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Background: Worldwide prevalence of generalized anxiety disorder (GAD) is considered high; in Europe lifetime
prevalence has been estimated at 4.3 to 5.9%. High levels of anxiety disorders have been reported in university
students, affecting 25 to 30% of the population. Young adults are some of the most vulnerable for the onset of
mental health disorders and any stressors may act as a catalyst for their onset. The absence of resources can often
mean that many do not seek treatment. Other factors that impede access to resources include such things as a lack
of trained professionals, personal stigma, and waiting lists. Anxiety disorders can be treated successfully; indeed
brief forms of cognitive-behavior therapy have been recommended. One potential avenue for research and
development is that of delivering low-intensity interventions online for students with GAD. Therefore, the current
study seeks to investigate the potential effectiveness for a low-intensity online CBT-based treatment for GAD in a
service-based setting; implemented as one step in a stepped-care model.
Methods/Design: The research is a service-based effectiveness study utilizing a randomized waiting-list controlled
design. The active intervention consists of six weekly modules of online CBT. Participants are assigned a supporter
who provides weekly post-session feedback on progress and exercises. Participants will complete the GAD-7 as
the primary outcome measure. Secondary outcomes include pathological worry, depression and measures of
well-being. At three-months follow-up data will be collected using the GAD-7, BDI-II, PSWQ, ED-Q5 and WSAS.
Post-session data will be collected on significant in-session events in treatment (HAT). A satisfaction with treatment
measure will be administered post-treatment (SAT).
Discussion: The study will be a contribution to the potential for a low-intensity internet-delivered program implemented
in a service-based setting; implemented as one step in a stepped-care model. The study will be a contribution to the
already established work in online treatments for anxiety worldwide. The study will assess the utility of an innovative
digital health solution (SilverCloud) to deliver such interventions.
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Anxiety disorders rank high among the most common
mental health disorders worldwide [1]. Anxiety disorders
include generalized anxiety disorder (GAD), panic dis-
order and agoraphobia (PD/A), panic attacks (PA), spe-
cific phobia (SP), and social anxiety disorder (SAD) [2].
In general, anxiety is characterized by excessive worry
about everyday events, irrespective of whether they are
internal or external or originating in the past, present or
future [2]. In Europe, 12-month prevalence of anxiety
disorders has been estimated at 14% [3-5].
GAD is typically considered a chronic condition; a
homogenous disorder characterized by excessive worry
affecting several domains including restlessness, fatigue,
difficulties concentrating, muscle tension, sleep distur-
bances, and irritability [6]. In Europe the lifetime preva-
lence of GAD has been estimated at 4.3 to 5.9%, with a
12-month prevalence of 1.2 to 1.9%, yet only a very small
percentage seek treatment [7]. GAD, like other mental
health disorders, often presents with comorbidity - princi-
pally mood disorders or other types of anxiety disorder
[4,8]. GAD is associated with significant deleterious
effects: economic, personal, intrapersonal and societal
[9,10], which can cause significant impairment and re-
duced quality of life for an individual and their family [11].
Anxiety and students
Several studies have reported elevated levels of anxiety
and stress in university students [12]. The prevalence of
anxiety in high school and university students has been
reported to be between 25 and 30%, in response to their
academic demands [13,14]. Academic stress is highly
prevalent and it can contribute significantly to anxiety
and depression among college students. For instance, a
recent survey of young adult students in Ireland using
the Depression Anxiety Stress Scale (DASS-21) [15],
showed levels of clinical anxiety at 36% (8% in the mild
range, 15% in the moderate range, 5% in the severe and
a further 9% in the very severe range) and 30% with cli-
nical symptoms of stress (10% in the mild range, 10% in
the moderate range and 10% in the severe (7%) to very
severe (3%) range) [16].
The transition to university and the management of
the resulting academic demands can be a stressful time
for many students. The majority of students are at a de-
velopmental stage where the onset of mental health diffi-
culties can arise and any stressors may act as a catalyst
for their onset [12,17,18]. Indeed, young adults aged be-
tween 17 and 25 are at high risk of developing a serious
mental illness such as an anxiety disorder, and whilst
sometimes mental disorders can be difficult to diagnose
early on, the risk of delayed diagnosis is often associated
with treatment resistance and poorer longer-term out-
comes [12]. The result of a lack of opportunity for earlydiagnosis and treatment can often mean academic failure
and dropping out of university. Furthermore, any such
underachievement or failure can have long-term conse-
quences on self-esteem and progress in future life [12].
Since the publication of the Royal College of Psychia-
trists updated report (2011) on the mental health of stu-
dents at university, there is no evidence of the abating of
the concerns that were previously raised [18] he demand
for counseling and mental health services among stu-
dents has only increased [12]. This is due to a broad
range of factors, including the rise of family breakdowns,
the increase in student monetary contributions to uni-
versity, the changing demographic of the student popu-
lation (with a greater diversity of international students),
and the case that many students now have to work to
survive, places an increased demand not only on their
time but also their mental health and wellbeing [12].
Treating anxiety disorders
Anxiety can be treated successfully through disorder spe-
cific treatment plans or treatments that target common
elements and symptoms across anxiety disorders [19,20].
Treatments for GAD include pharmacological and psy-
chological and both have demonstrated their efficacy [21].
By far the most extensively researched psychological treat-
ment for GAD is cognitive-behavior therapy (CBT) which
has been shown to be a highly effective treatment for
GAD [22]. Different cognitive and behavioral techniques
compose any treatment for GAD. They can include cogni-
tive restructuring, behavioral exposure, worry exposure
(staying with feared outcomes), relaxation training, and
problem solving, among others. CBT for GAD aims to
help the user overcome emotional avoidance and learn
that their anxiety is not debilitating, but can be managed
and indeed recede over time [23-25].
To date a number of theoretical models have been pro-
posed for GAD [26]. Perhaps the most well-defined and
empirically supported of these are the Avoidance Model
of Worry and GAD (AMW) [27] and the Intolerance of
Uncertainty Model (IUM) [28]. Both have gathered sup-
porting empirical evidence for their central constructs and
have developed and researched treatment protocols based
on their model [26]. The IUM is largely a cognitive model
explaining the pathogenesis of GAD, whereas the AMW
is an integrated model that includes cognitive alongside
emotional and behavioral components. The treatment
protocol used in this study is largely based on the AMW
model of GAD.
It is the case that many with anxiety disorders have no
diagnosis nor seek treatment [29,30]. Consequently,
mental health disorders such as anxiety disorders often
go undetected, especially where accessing psychological
services is difficult and/or services are overburdened, as
is the case for many university institutions [12,31].
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lack of available trained professionals, waiting lists, lack of
motivation for change, negative perception of psycho-
logical treatments, indirect costs of treatment (and direct
costs in some cases), personal difficulty such as stigma,
and low mental health literacy. Each of this barriers can
play an important role in choosing whether or not to seek
diagnosis and treatment [32,33].
CBT as a brief psychological interventions has demon-
strated its efficacy and has the potential to significantly re-
duce the burden of anxiety disorders [34]. CBT is highly
suitable to being delivered as a low-intensity intervention
within a model of stepped-care [35]. Ireland is far behind
its European neighbors in developing and implementing
stepped-care models for mental health service delivery
that involve both low-intensity (such as bibliotherapy) and
high-intensity (such as face-to-face therapy) interventions,
despite it being recommended as best practice [36] and its
demonstrated success to date [37].
Stepped-care model of treatment
The central idea in developing stepped-care models in
mental health is to extend access [38]. In recent years
attempts to overcome barriers to access have been ad-
dressed through the development and implementation
of a wide range of low-intensity interventions including
internet-delivered treatment programs. Programs have
been developed and employed in the treatment of a
range of disorders and their results support their efficacy
[39-42]. Internet-delivered treatments for anxiety disor-
ders have included interventions for panic disorder,
SAD, SP, and posttraumatic stress and they have estab-
lished findings that support their potential effectiveness
and efficacy [43-47].
More precisely, a number of studies have investigated
the potential for internet-delivered treatments for GAD
and they have reported significant post-treatment and
follow-up gains [33,48-51] similar to those found in face-
to-face treatment studies [52]. A recent meta-analysis of
internet-delivered treatments for GAD demonstrated large
post-treatment effects for GAD symptoms (d = 0.91) and
pathological worry (d = 0.73) in favor of the active inter-
ventions when compared to waiting list control groups
[53]. In addition, online studies for anxiety treatment that
provide human support yield enhanced results when com-
pared to those with no human support [54]. The demand
for psychological treatments will never be met from high-
intensity therapy, therefore internet-delivered treatments
are a valuable alternative.
Delivering online low-intensity interventions for GAD
The internet offers the possibility of delivering a treat-
ment intervention at low cost and perhaps overcoming
some of the barriers to access mentioned earlier. Onlinetechnologies can deliver treatment incrementally and in
an engaging way. Furthermore, internet penetration in
Ireland is at 76.8% [55] and it is likely that it is an
attractive medium, especially for younger people as they
are already high users of the internet and related tools.
In a recent Irish survey that asked a student sample
about the places they were likely to use as a source of
support, the internet was the highest scoring answer at
78%, above friends, parents, doctors, or other profes-
sionals [16].
Some previous research has assessed the relevance of
low-intensity internet-delivered treatments for anxiety
disorders in service-based settings [56-58]. However,
only a handful of studies have investigated the efficacy and
effectiveness of low-intensity internet-delivered treatments
for GAD [33,48-51]. The current study seeks to make a
contribution towards understanding the relevance of a
low-intensity internet-delivered treatment for GAD in
a service-based setting in Ireland.
Therefore, using established CBT principles informing
skills and strategies for the management of GAD in an
integrated disorder-specific treatment plan, the study
aims to deploy these using a novel digital health software
platform (SilverCloud SilverCloudHealth Ltd., The
Priory, John’s Street West, Dublin 8, Ireland.) that inte-
grates a number of innovative engagement strategies for
improving the user experience: personal, interactive,
supportive, and social [59]. The details of the platform
and the content of treatment are described in more de-
tail below.
Dropout from online treatments
A problem that has faced online treatments in general,
and more particularly self-administered treatments with-
out support, is that of dropout [60]. Dropout is a con-
tinued cause of concern as it is suggested that completing
the entire course will benefit users, although several online
studies have reported benefits for users who have not
completed the entire course of treatment [61]. Some stu-
dies have collected information regarding dropout, sug-
gesting difficulties using the computer, negative features
of the program, perceiving the course as too demanding,
poor clinical progress, receiving alternative treatment,
feeling better, lack of time, and problems understanding
the computer program [42,62]. The technology used in
the current study has been specifically designed to include
a number of engagement strategies for improving the user
experience: personal, interactive, supportive, and social.
An investigation of dropout will be valuable in assessing
the user’s experience of online delivery.
Objectives of the trial
The study aims to implement and evaluate the effective-
ness of a low-intensity online self-administered treatment
Richards et al. Trials 2014, 15:145 Page 4 of 11
http://www.trialsjournal.com/content/15/1/145for anxiety (with support) for students with GAD symp-
toms. There are four research questions. Firstly, can an
online treatment for GAD symptoms be effective for an
adult student population in a service-based setting? Se-
condly, what do participants find helpful and hindering in
their online treatment for GAD symptoms? Thirdly, are
participants satisfied with accessing and using an online
treatment? Fourth and finally, what are the reasons for
dropout from an online treatment?
Based on the success that has been achieved with sup-
ported online treatments in general [42,54,63,64] and with
internet-delivered interventions for GAD [33,48-51,65],
we hypothesize that participants in the trial will de-
monstrate significant decreases in GAD symptoms post-
intervention and a corresponding positive change in
pathological worry and quality of life.
Methods/Design
Study design
The research is a service-based effectiveness study uti-
lizing a randomized controlled trial design of an internet
intervention for the treatment of GAD symptoms. Partici-
pants will be randomized into two groups: the internet-
delivered intervention with clinical support and a waiting
list control group. The study protocol, information on the
study, informed consent and related materials received
ethical approval from the School of Psychology, Trinity
College Dublin (22 November 2013).
Sample size
Previous studies of online interventions for GAD that
have used a CBT protocol similar to the intervention in
the current study have reported post-treatment effect
sizes of between 0.79 and 1.67, and follow-up effects of
between 0.69 and 1.65, based on sample sizes ranging
from 10 to 97 [33,48-50]. We calculated power using
G-Power software [66]. Using a power of 0.80 and an
alpha of 0.05, we would need 50 subjects in each arm of
the trial to observe a moderate (d = 0.50) post-treatment
difference on the main outcomes.
Eligibility criteria
All registered students at the University of Dublin, Trinity
College, Dublin, will be eligible to participate. The study
will therefore consist of adult primary care patients ful-
filling the Diagnostic and Statistical manual for Mental
Health Disorders – Version 5 (DSM-5) [2] criteria for
generalized anxiety symptoms. It is the case that all par-
ticipants will have clinically meaningful generalized an-
xiety symptoms. Participants with comorbid disorders,
such as mood disorders will be included once GAD is the
primary diagnosis. On screening participants, eligibility
criteria include that participants are at least 18 years of
age and have a DSM-IV congruent score of 10 or aboveon GAD-7. Participants attending face-to-face counseling
will be excluded.
Recruitment
Registered students at the University of Dublin, Trinity
College, Dublin, will receive an email advertising the
study and inviting students to take part. Interested stu-
dents will be able to visit a website to receive more
information on the study, what will be involved in par-
ticipating, the treatment, and how to make contact and
proceed with screening. On agreeing to participate, in-
formed consent will be completed online and thereafter
the baseline screening questionnaires.
Randomization
Using computer algorithms to score screening in-
struments at baseline, participants will be automatically
randomized to either the active intervention group or a
waiting list control group. Participants will be imme-
diately informed about the randomization outcome. The
randomization procedure will be managed by a person
independent of the research group.
Interventions
Silver Cloud platform
Delivered through the SilverCloud platform, the pro-
gram for the treatment of GAD employs several in-
novative engagement strategies for improving the user
experience. These are divided into several categories:
personal, interactive, supportive, and social.
Personal
The user has his or her own secure homepage, and can fill
in a profile with basic information about themselves. As
well as establishing a sense of ownership, this information
is also useful for the supporter, allowing the supporter to
provide more personal feedback. The homepage is
intended to provide a reflective space; the user can docu-
ment their thoughts and feelings, and these can be elabo-
rated on within the journal application, which also acts as
the vehicle for therapeutic writing exercises. The user has
actions suggested to them, and as they complete modules
of the program their achievements are noted. Users are
free to access the modules in any order they wish, in either
a linear or non-linear manner, contributing to a sense of
empowerment. Alongside the central content, a range of
satellite applications are provided, such as a goal-setting
application which can be used independently of the
program content. Applications are released as the user
completes modules, with the intention of maintaining
engagement by introducing new features over time and
not overwhelming the user initially. Users can also control
which applications appear on their home page.
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The program includes a number of interactive elements
and graphical exercises which are aimed at engaging users
with the therapeutic content, for example, reflecting on
their own thinking style. Users also have the ability to re-
spond to content, indicating whether they like it, and also
to comment on it. Both exercises and comments can be
explicitly shared with the supporter. The user is provided
with immediate feedback wherever possible; for example,
when a charting exercise such as a mood chart is com-
pleted, the application item is graphically updated on the
home page. Likewise, items are ticked off on the to-do list
when completed and achievements are unlocked in each
module summary.
Supportive
Each user has an assigned supporter who provides weekly
reviews of their progress on the program. This support is
asynchronous, whereby the supporter sets a date to review
their user’s progress, and they do not provide feedback,
support or contact outside this time. The supporter can
support multiple users, logging in once weekly for in-
stance, and reviewing the work of all their online users
within an allocated time period. Such asynchronous online
contact may be logistically easier to implement for many
services compared to motivational interviewing and tele-
phone support. The system supports the exchange of mes-
sages between the user and supporter, but goes beyond
email as the user is encouraged to share their content
(such as completed exercises and comments) with their
supporter. This shared content allows the supporter to
respond in a more personal way and provide guidance as
well as encouragement to keep using the program. Ad-
herence information is also available to the supporter, and
they can keep track of the user’s progress. This is all
personally sensitive information, and so a shared view is
provided in the user interface where they can see the sup-
porter’s view of their data. By making the visibility of user
data to the supporter more transparent, as well as the
ability to explicitly change the sharing status of data, the
user is provided with a greater sense of control while
facilitating a meaningful interaction with the supporter.
Social
While group therapy and peer group support are well
established, introducing contact with other users within
any online system raises a number of ethical concerns
regarding the possibility for unhelpful or negative con-
tent or communications. As a first step, the user can see
anonymous indications of other people in the system.
The intention is to reassure users that they are not alone
in experiencing difficulties and that many other people
have experienced similar problems and overcome them.
Users can respond to content by indicating that they‘like’ it, and can see how many other people liked it,
helping to reduce the sense of isolation. Other more de-
tailed shared content (such as tips and ideas) is subject
to supporter moderation.
Computerized cognitive-behavior therapy (cCBT) program
Calming Anxiety is a six-module online CBT-based
intervention for GAD. The structure and content of the
program modules follow evidence-based principles of
CBT for GAD treatment based on the AMW model of
GAD [27]. The treatment comprises cognitive, emotional,
and behavioral components that include self-monitoring,
relaxation training, self-control desensitization, gradual
stimulus control, cognitive restructuring, and worry out-
come monitoring [26]. The treatment is delivered on a
Web 2.0 platform using media-rich interactive content.
The content of each module is described briefly in Table 1
below. Each module is structured in an identical way and
incorporates introductory quizzes, videos, informational
content, interactive activities, as well as homework sug-
gestions and summaries. In addition, personal stories and
accounts from other clients are incorporated into the
presentation of the material.
Waiting list control
Participants in the waiting list control group will not re-
ceive any treatment for the duration of the intervention
for the immediate treatment group (six weeks). At week
seven the waiting list participants will be given access to
treatment under the same conditions as the immediate
treatment group received (Figure 1).
Support during treatment
Each participant will be assigned a supporter who will
monitor participant’s progress throughout the trial. Once
a participant is assigned to the active treatment condi-
tion at their first login there will be a message from their
supporter. This message welcomes them to the program,
highlights aspects of the program, and encourages them
in the use of the program. Each week the supporters will
login and review participants progress, leaving feedback
for them and responding to the work they have com-
pleted. Participating supporters will receive training in
the program and how to deliver feedback.
Supporters will be graduate psychology students and
will be qualified to at least masters level, some with doc-
torates. Each supporter will be assigned participants to
provide post-session feedback of between 10 and 15 mi-
nutes per participant per session.
Assessments
At baseline, assessments (see Table 2) including Sociode-
mographics & History Questionnaire, Generalized Anxiety
Disorder-7 (GAD-7), Penn State Worry Questionnaire
Table 1 Calming anxiety: description of module content
Module name Brief description
Getting Started Outlines the basic premise of CBT and provides some information about anxiety. Users are encouraged
to explore their current difficulties with anxiety and to begin monitoring their anxiety levels.
Understanding Moods and
Emotions
This module describes the behavioral, physical, and emotional aspects of the Thoughts-Feelings-Behaviour (TFB)
cycle. The user is introduced to relaxation practices. Users start to build their own anxiety-related TFB cycles
Anxious thoughts and worry This module focuses on noticing anxious thoughts and worry, and ways of relating to these thoughts,
including acceptance, distraction, and ‘worry time’.
Face your Anxiety, Step by Step This module outlines why avoidance is harmful, and breaks down the steps needed for successful graded exposure.
Users are encouraged to build their own fear hierarchies and to begin working through them.
Challenge your Anxious
Thoughts
This module explains negative automatic thoughts, their role in anxiety, and how to challenge them. Users are
encouraged to challenge the thoughts in their TFB cycles, and make use of helpful thoughts.
Bringing it all Together. In this final module, users are encouraged to bring together all the skills and ideas they have gathered so far, note
their personal warning signs, and make a plan for staying well.
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Social Adjustment Scale (WSAS), and EuroQol (ED-Q5)
will be completed for screening purposes. Thereafter the
GAD-7, PSWQ, BDI-II, ED-Q5 and WSAS will be com-
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Figure 1 Flowchart of the study CONSORT.active treatment group and the waiting list participants).
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Table 2 Study measures to be used
Measure Assessment Time of assessment
Generalized Anxiety Disorder-7 (GAD-7) Anxiety symptoms Baseline, post-treatment and follow-up
Sociodemographic & History Questionnaire Gender, age, marital status, education, occupation,
socioeconomic status, and history
Baseline
Penn State Worry Questionnaire (PSWQ) Symptoms of anxious worry Baseline, Post-treatment and follow-up
Beck Depression Inventory (BDI-II) Depression symptoms Baseline, post-treatment and follow-up
EuroQol (EQ-5D-5 L) Quality of Life indicators Baseline, post-treatment and follow-up
Work and Social Adjustment Scale (WSAS) Work and Social Adjustment scale Baseline, post-treatment and follow-up
Engagement and Usage data Engagement and usage Continuous
Satisfaction with Treatment (SAT) Satisfaction with therapy Post-treatment
Helpful and Hindering Aspects of Therapy (HAT) Helpful and hindering aspects of therapy After each session
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(HAT). The measure Satisfaction with Treatment (SAT)
will be administered at week six.Measures
Primary outcome
The General Anxiety Disorder questionnaire (GAD-7)
[67] comprises seven items measuring the symptoms and
severity of GAD based on the DSM-IV diagnostic criteria
for GAD. The GAD-7 has good internal consistency (0.89)
and good convergent validity with other anxiety scales
[68]. Increasing scores indicate a greater severity of symp-
toms [69]. Scores of 5, 10, and 15 are taken as the cutoff
points for mild, moderate, and severe anxiety, respectively.
The GAD-7 is increasingly used in large-scale studies as a
generic measure of changes in anxiety symptomatology
[37,70]. Using the threshold score of 10, the GAD-7 has a
sensitivity of 89% and a specificity of 82% for GAD; it is
considered congruent of DSM-IV as a clinical case for
GAD [67].Secondary outcomes
The Sociodemographic Information & History question-
naire is based on the History Questionnaire used in an
earlier study [61]. It will be developed for the present
study and will collect demographic details of the partici-
pants. It will collect data on any previous diagnosis of
anxiety disorders and on the length of time that one
experiences anxiety symptoms. It will collect data on
participant’s experience of counseling and therapy, and
medication for anxiety. The questionnaire will collect
data on whether one has a previous diagnosis of an
organic mental health disorder such as schizophrenia,
psychosis, or bipolar disorder. In addition it contains
items related to the comorbidity of anxiety with the
presence of psychosis, alcohol and drug misuse, and/or
any recent medical diagnosis.The Penn State Worry Questionnaire (PSWQ) [66]
consists of 16 items and is considered a valid clinical
measure of the worry characteristic of GAD. Each item is
measured on a 5-point Likert scale (1 - not at all typical of
me to 5 - very typical of me) and a total score ranging
between 0 and 80 is calculated by summing all items.
Psychometric evaluations have revealed a high internal
consistency (α = 0.86 to 0.95) and test-retest reliability
over four weeks (r = 0.74 to 0.93) [71]. The measure is able
to differentiate between patients with GAD and those with
other anxiety disorders [72].
The 21-item Beck Depression Inventory - Second Edition
(BDI-II) [73] is a widely used questionnaire developed for
the assessment of depressive symptoms that correspond to
the criteria for depressive disorder diagnosis as outlined in
The American Psychiatric Associations Diagnostic and
Statistical Manual of Mental Disorders - Fourth Edition
(DSM-IV) [74]. Each item is scored on a scale from 0 to 3.
The BDI-II manual states that a cutoff score of 17 has
yielded a 93% specificity and 18% sensitivity for the pre-
sence of major depression (Beck et al. [73]). The scale
designates levels of severity: minimal (0 to 13); mild
(14–19); moderate (20 to 28); and severe (29 to 63) [73].
The BDI-II has been found to have an excellent internal
consistency and test–retest reliability with a diverse range
of samples [73,75,76]. The BDI-II has demonstrated a
good convergent validity with other measures of depres-
sion among clinical and nonclinical adult samples [77].
The EuroQol 5D (EQ-5D) questionnaire [78] is a
generic instrument of health-related quality of life. Part
one records self-reported problems in each of five do-
mains: mobility, self-care, usual activities, pain and/or
discomfort and anxiety and/or depression. Each domain
is divided into three levels of severity corresponding to
no problems, some problems, and extreme problems,
which allows a population-based preference score or
societal index (SI) to be obtained. Part two records the
subjects self-assessed health on a Visual Analogue Scale
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imaginable health states score 100 and 0, respectively.
The Work and Social Adjustment (WSA) question-
naire [79] is a simple, reliable, and valid measure of im-
paired functioning. It is a five-item self-report measure
that provides an experiential impact of a disorder from
the patient’s point of view. It looks at how the disorder
impairs the patient’s ability to function day-to-day on
five dimensions: work, social life, home life, private life,
and close relationships.
Other participant measures
The Helpful Aspects of Therapy Form (HAT) [80,81] is
an instrument that assesses the most significant events
in the therapy. Participants are asked to describe in their
own words anything they engaged with in the session
that was helpful or hindering for them.
The Satisfaction with Treatment (SAT) questionnaire
[82] establishes a net promoter score that serves as a
tool to gauge customer satisfaction. It includes one ques-
tion: How likely is it that you would recommend this
treatment to a friend or colleague? The measure also
asks several other quantitative questions regarding satis-
faction with accessing treatment online. The satisfaction
measure contains two qualitative questions asking par-
ticipants to describe what they most liked and least liked
about the online treatment.
The pre-treatment and during treatment dropout
questionnaires are two simple questionnaires, one asking
about the reasons for deciding to dropout without be-
ginning treatment and the second asking about the rea-
sons for dropping out during treatment. The link for
each of these will be contained in the appropriate emails
that supporters send to their respective participants, fol-
lowing the protocol. Pre-treatment dropout: after one
week the supporter can send the questionnaire by email.
Participants discontinue treatment: after one missed ses-
sion the supporter should send a reminder message to
the participant by email. If after one further week the
participant has not responded, the supporter can send
the questionnaire asking about the reasons for dropout.
Engagement and usage data
The online system will collect anonymized descriptive
information relating to engagement and usage. Data col-
lected will include the number of sessions completed,
mean time spent on the program, average number of ses-
sions per user, and average length of a session. A session
is defined as an instance where a user logs onto the sys-
tem. Session time estimation will always be an imperfect
calculation, as users may be interrupted or take breaks
within a session, and may not formally log out of the sys-
tem. All client activity within the system such as reading
content pages, saving a journal entry, or updating anactivity, is logged with a time stamp. Starting with the log
entry of the client logging on, the total time is calculated
by adding up the time that elapses between each sub-
sequent log record (in the same manner as popular web
analytics software). On its own, this will yield a result vul-
nerable to overestimation of session time. To avoid coun-
ting periods where the user is not actively engaged with
the system, any interactions taking longer than 30 minutes
are counted as 1 minute. Any period of inactivity longer
than three hours will start the count on a new session, ra-
ther than extending the time of the current session. Use of
different program components will be measured. Data re-
lated to supporter reviews will be collected.
Ethical considerations
Information made available to all prospective participants
will inform them of exactly what is involved in participa-
ting, including the objectives of the trial and its impor-
tance. Participants will be informed of the importance of
the waiting list control group. Informed consent will be
obtained from each participant before randomization. Par-
ticipants will know that their involvement is voluntary and
they can withdraw their participation at any time without
prejudice. Informed consent is collected online through
participants digital signature and is returned online.
Planned statistical analysis
The analyses will be based on the intention-to-treat
principle, including those who began treatment and pro-
vided follow-up data irrespective of treatment compliance.
Missing data will be handled using Last Observation
Carried Forward (LOCF). Effects will be tested at the 0.05
level. Analysis of variance (ANOVA)will be used to inves-
tigate any baseline demographic or clinical differences
between the groups.
To test the main hypotheses, repeated measures
ANOVA will be performed for the primary outcome
measure for anxiety (GAD-7). Thereafter ANOVAs will
be executed for the BDI-II, PSWQ, EQ-5D and WSAS.
Contrasts will be conducted comparing changes from
baseline to post-treatment for each group separately.
Further analysis of baseline demographic variables and
any relation to outcomes will be conducted. Effect sizes
(Cohen’s d) will be calculated both within and between
groups, based on the pooled standard deviation. For
Cohen's d an effect size of 0.2 to 0.3 can be considered a
small effect, around 0.5 a medium effect, and 0.8 up-
wards a large effect [83].
Analysis will be made to determine the proportion of
participants who make a clinically meaningful change at
the end of treatment and at follow-up. Pre-treatment,
post-treatment, and follow-up GAD-7, BDI-II and PSWQ
scores will be compared with clinical cutoffs to provide an
indicator of remission. Remission is defined as the number
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blished clinical cutoffs, and then at post-treatment and
follow-up scored below the established clinical cutoffs:
GAD-7 total score <10 [67]; BDI-II total score <14 [84],
PSWQ <45 [85], and WSAS <10 [79]. In addition, we will
calculate the relative risk of anxiety and depression by
dividing the event rate (anxiety or depression) post-
treatment by the event rate pre-treatment [70]. An estima-
tion of recovery will be made by identifying the number of
participants in each group who demonstrated a reduction
of 50% of pre-treatment GAD-7, BDI-II and PSWQ scores
[70]. In addition we will also calculate the number of reli-
ably changed and recovered participants using Jacobson
and Truax’s [86] criteria.
HAT data will be analyzed qualitatively following the
descriptive and interpretative framework described by
Elliott and Timulak [87]. Participants’ responses will be
considered within domains of helpful and non-helpful
events and impacts. Firstly, individual units of text that
could stand meaningfully out of their context will be
identified. Next each of these will be organized into do-
mains of helpful events and helpful impacts. Similar
events and impacts will be grouped into categories,
which will be then finalized and suitably named and
defined. The process is organic, involving constant refe-
rence to the source data [88].
SAT data [82] will firstly establish the net promoter
score. Descriptive statistics will be used to report on
other quantitative questions, and qualitative data will be
analyzed following the descriptive and interpretative
framework described by Elliott and Timulak [87]. Simi-
larly, data from dropout pre-treatment and during treat-
ment will be analyzed qualitatively.Discussion
This study seeks to evaluate the effectiveness of an
internet-delivered treatment for GAD in a sample of stu-
dents in Ireland. The study will be a contribution to the
potential for a low-intensity internet-delivered program
implemented in a service-based setting. The study will
be a contribution to the already established work in on-
line treatments for anxiety worldwide.
The primary outcome measure (GAD-7) that will as-
sess anxiety symptoms is a well-established measure and
has been used in previous trials involving internet-
delivered and face-to-face treatments. The secondary
outcome measures (BDI-II, PSWQ) will each give an
insight into participant’s improvements, principally in
pathological worry (a central construct in GAD) and any
corresponding improvements in comorbid depressive
symptoms. The WSAS and ED-Q5 will assess any im-
provements in quality of life indicators corresponding to
improvements in anxiety symptoms for participants.The other secondary outcome measures (HAT, SAT)
that we have included in the study will contribute to what
participants find satisfying with online treatments and fur-
ther will detail what in-session events and their impacts
participants report as being helpful or hindering in their
online treatments [82,88].
It is also hoped that with the inclusion of pre-treatment
and during treatment dropout questionnaires, the study
can make a contribution to developing a better under-
standing of the reasons for dropout in online treatments.
The results may not be generalizable to the wider com-
munity in Ireland, but perhaps may give insight into the
usefulness of low-intensity internet-delivered interven-
tions within a stepped-care model in routine primary care.
The internet-based intervention is interesting for adult
students who are high users of the internet and related
tools, who look for alternative healthcare [53] as a prefe-
rence, and because the possibility of accessing traditional
services is difficult, prohibitive due to waiting lists, costs,
and personal stigma.
Trial status
This trial began in January 2014. We are currently be-
ginning a second round of recruitment.
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